In contrast, in other tumours, high expression levels of IL-6 have been correlated with impaired survival in triple-negative breast cancer, ovarian cancer and colorectal cancer and have been detected in the serum of metastatic prostate cancer patients [24–27]. This evidence concerns the gene IL6 and metastatic prostate carcinoma.